ADI PEG20

Phase 3Small molecule

PPolaris Group

ADI PEG20 is one of 167 small molecule programs targeting Leiomyosarcoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

166

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeiomyosarcomaActive, not recruiting

Uveal MelanomaActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

ObesityActive, not recruiting

Soft Tissue SarcomaTerminated

LeiomyosarcomaPhase 3

Active, not recruiting

Uveal MelanomaPhase 1

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

ObesityPhase 2

Active, not recruiting

Soft Tissue SarcomaPhase 3

Terminated

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

ADI PEG20

PPolaris Group

Phase 3

2 2

Viread

Gilead

Preclinical

1 3

Sovaldi

Gilead

Preclinical

1 4

Hepsera

Coreg

2 6

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 7

Vermox

WWim Janssens

Preclinical

1 8

Opdivo

Bristol-Myers Squibb

Preclinical

2 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Hepatocellular Carcinoma

NCT06034977

Q1 2028

Phase 2Recruiting

NASH

NCT05842512

Q2 2028

Phase 1Active, not recruiting

Soft Tissue Sarcoma

NCT05813327

Q4 2028

Phase 3Recruiting

Hepatocellular Carcinoma

NCT05317819

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma2 trials

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Active, not recruiting·WWashington University School of Medicine·Phase 1·NCT05813327·6 enrolled

ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial

Terminated·PPolaris Group·Phase 3·NCT05712694·218 enrolled

Hepatocellular Carcinoma2 trials

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Recruiting·PPolaris Group·Phase 3·NCT05317819·300 enrolled

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Recruiting·—·Phase 2·NCT06034977·120 enrolled

Carboplatin1 trial

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

Withdrawn·QQueen Mary University of London·Phase 1·NCT03498222

NASH1 trial

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Recruiting·PPolaris Group·Phase 2·NCT05842512·60 enrolled

Uveal Melanoma1 trial

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03922880·9 enrolled

2 more indications

Advanced Solid Cancers1 trial

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Terminated·PPolaris Group·Phase 1·NCT03254732·33 enrolled

Obesity1 trial

ADI-PEG20, Obesity and Prediabetes

Withdrawn·WWashington University School of Medicine·Phase 2·NCT05829239

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for ADI PEG20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ADI PEG20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ADI PEG20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Polaris Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPolaris Group

ADI PEG20

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2028

Q2 2028

Q4 2028

Trials by Indication[1]

Soft Tissue Sarcoma2 trials

Hepatocellular Carcinoma2 trials

Carboplatin1 trial

NASH1 trial

Uveal Melanoma1 trial

Advanced Solid Cancers1 trial

Obesity1 trial

References

Drug Info

Quick Facts

Related News